By Rob Otman AstraZeneca (NYSE: AZN) is a large cap company that operates within the pharmaceutical industry. Its market cap is $92 billion today and the total one-year return is 24.61% for shareholders.
AstraZeneca stock is beating the market, and it reports earnings soon. But does that make it a good buy today? To answer this question we’ve turned to the Investment U Stock Grader. Our research team built this system to diagnose the financial health of a company.
Our system looks at six key metrics…
[iu-adbox]
✗ Earnings-per-Share (EPS) Growth: AstraZeneca reported a recent EPS growth rate of -29.45%. That’s below the pharmaceutical industry average …read more
